SE9702000D0 - New pharmaceutical formulation - Google Patents

New pharmaceutical formulation

Info

Publication number
SE9702000D0
SE9702000D0 SE9702000A SE9702000A SE9702000D0 SE 9702000 D0 SE9702000 D0 SE 9702000D0 SE 9702000 A SE9702000 A SE 9702000A SE 9702000 A SE9702000 A SE 9702000A SE 9702000 D0 SE9702000 D0 SE 9702000D0
Authority
SE
Sweden
Prior art keywords
omeprazole
pct
active ingredient
enantiomer
sec
Prior art date
Application number
SE9702000A
Other languages
English (en)
Swedish (sv)
Inventor
Magnus Erickson
Lars Josefsson
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407122&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9702000(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9702000A priority Critical patent/SE9702000D0/xx
Publication of SE9702000D0 publication Critical patent/SE9702000D0/xx
Priority to HR980260A priority patent/HRP980260B1/xx
Priority to ARP980102246A priority patent/AR012698A1/es
Priority to MA25077A priority patent/MA26497A1/fr
Priority to TW87107541A priority patent/TW575435B/zh
Priority to NZ500886A priority patent/NZ500886A/en
Priority to CN98805564A priority patent/CN1123338C/zh
Priority to ES98924700T priority patent/ES2195342T3/es
Priority to AT98924700T priority patent/ATE234078T1/de
Priority to IL13289598A priority patent/IL132895A0/xx
Priority to CA002290531A priority patent/CA2290531C/en
Priority to DZ980104A priority patent/DZ2494A1/xx
Priority to RU99126869/14A priority patent/RU2207121C2/ru
Priority to SK1590-99A priority patent/SK286625B6/sk
Priority to SI9830433T priority patent/SI0984773T1/xx
Priority to TR1999/02890T priority patent/TR199902890T2/xx
Priority to KR1019997011083A priority patent/KR100540721B1/ko
Priority to AU76803/98A priority patent/AU722879B2/en
Priority to EEP199900540A priority patent/EE03903B1/xx
Priority to ZA984178A priority patent/ZA984178B/xx
Priority to DK98924700T priority patent/DK0984773T3/da
Priority to PL98337237A priority patent/PL194634B1/pl
Priority to YUP-608/99A priority patent/RS49629B/sr
Priority to CZ0420299A priority patent/CZ298972B6/cs
Priority to DE69812089T priority patent/DE69812089T2/de
Priority to IDW991448A priority patent/ID24654A/id
Priority to EP98924700A priority patent/EP0984773B1/en
Priority to US09/077,717 priority patent/US6090827A/en
Priority to HU0002182A priority patent/HU229154B1/hu
Priority to JP50056299A priority patent/JP4649001B2/ja
Priority to BR9809484-0A priority patent/BR9809484A/pt
Priority to UA99116247A priority patent/UA71541C2/uk
Priority to PCT/SE1998/000922 priority patent/WO1998053803A1/en
Priority to PT98924700T priority patent/PT984773E/pt
Priority to TNTNSN98068A priority patent/TNSN98068A1/fr
Priority to EG56898A priority patent/EG24044A/xx
Priority to MYPI98002355A priority patent/MY122298A/en
Priority to SA98190304A priority patent/SA98190304B1/ar
Priority to IS5245A priority patent/IS2856B/is
Priority to NO19995809A priority patent/NO328100B1/no
Priority to HK00105002A priority patent/HK1025744A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SE9702000A 1997-05-28 1997-05-28 New pharmaceutical formulation SE9702000D0 (sv)

Priority Applications (41)

Application Number Priority Date Filing Date Title
SE9702000A SE9702000D0 (sv) 1997-05-28 1997-05-28 New pharmaceutical formulation
HR980260A HRP980260B1 (en) 1997-05-28 1998-05-14 Pharmaceutical formulation of omeprazole
ARP980102246A AR012698A1 (es) 1997-05-28 1998-05-14 Formulacion farmaceutica de omeprazol
MA25077A MA26497A1 (fr) 1997-05-28 1998-05-15 Nouvelle formulation pharmaceutique
TW87107541A TW575435B (en) 1997-05-28 1998-05-15 Pharmaceutical formulation of omeprazole
PCT/SE1998/000922 WO1998053803A1 (en) 1997-05-28 1998-05-18 Pharmaceutical formulation of omeprazole
PT98924700T PT984773E (pt) 1997-05-28 1998-05-18 Formulacao farmaceutica a base de omeprazole
ZA984178A ZA984178B (en) 1997-05-28 1998-05-18 Pharmaceutical formulation of omeprazole
YUP-608/99A RS49629B (sr) 1997-05-28 1998-05-18 Farmaceutska formulacija omeprazola
ES98924700T ES2195342T3 (es) 1997-05-28 1998-05-18 Formulacion farmaceutica de omeprazol.
AT98924700T ATE234078T1 (de) 1997-05-28 1998-05-18 Pharmazeutische omeprazol-formulierung
IL13289598A IL132895A0 (en) 1997-05-28 1998-05-18 Pharmaceutical formulation of omeprazole
CA002290531A CA2290531C (en) 1997-05-28 1998-05-18 Pharmaceutical formulation of omeprazole
DZ980104A DZ2494A1 (fr) 1997-05-28 1998-05-18 Composition pharmaceutique d'oméprazole.
RU99126869/14A RU2207121C2 (ru) 1997-05-28 1998-05-18 Фармацевтический препарат омепразола
SK1590-99A SK286625B6 (sk) 1997-05-28 1998-05-18 Farmaceutický prípravok na báze omeprazolu
SI9830433T SI0984773T1 (en) 1997-05-28 1998-05-18 Pharmaceutical formulation of omeprazole
TR1999/02890T TR199902890T2 (xx) 1997-05-28 1998-05-18 Omeprazol�n farmas�tik form�lasyonu
KR1019997011083A KR100540721B1 (ko) 1997-05-28 1998-05-18 오메프라졸의 제약 제제
AU76803/98A AU722879B2 (en) 1997-05-28 1998-05-18 Pharmaceutical formulation of omeprazole
EEP199900540A EE03903B1 (et) 1997-05-28 1998-05-18 Omeprasooli ravimvorm
NZ500886A NZ500886A (en) 1997-05-28 1998-05-18 Enteric coated oral formulation comprising omeprazole and optionally an alkaline reacting compound and preparation where the light transmission at cloud point comprises the HPMC dissolved in a concentration of 1.2% (w/w) in a mixed solution of phosphate buffer 0.235M and pH 1.2
DK98924700T DK0984773T3 (da) 1997-05-28 1998-05-18 Farmaceutisk formulering med omeprazol
PL98337237A PL194634B1 (pl) 1997-05-28 1998-05-18 Doustny preparat farmaceutyczny, sposób jego wytwarzania, zastosowanie hydroksypropylometylocelulozy i zastosowanie preparatu farmaceutycznego
CN98805564A CN1123338C (zh) 1997-05-28 1998-05-18 奥美拉唑的药物制剂
CZ0420299A CZ298972B6 (cs) 1997-05-28 1998-05-18 Farmaceutický prostredek z omeprazolu
DE69812089T DE69812089T2 (de) 1997-05-28 1998-05-18 Pharmazeutische omeprazol-formulierung
IDW991448A ID24654A (id) 1997-05-28 1998-05-18 Formulasi farmasi omeprazola
EP98924700A EP0984773B1 (en) 1997-05-28 1998-05-18 Pharmaceutical formulation of omeprazole
US09/077,717 US6090827A (en) 1997-05-28 1998-05-18 Pharmaceutical formulation of omeprazole
HU0002182A HU229154B1 (en) 1997-05-28 1998-05-18 Pharmaceutical formulation of omeprazole
JP50056299A JP4649001B2 (ja) 1997-05-28 1998-05-18 オメプラゾール製剤
BR9809484-0A BR9809484A (pt) 1997-05-28 1998-05-18 Formulação farmacêutica oral revestida entérica, processo para a manufatura da mesma, uso de uma qualidade de hidroxipropil metilcelulose (hpmc) de baixa viscosidade, e, processo para o tratamento de doenças gastrointestinais em mamìferos, incluindo o homem.
UA99116247A UA71541C2 (uk) 1997-05-28 1998-05-18 Фармацевтична композиція на основі омепразолу
TNTNSN98068A TNSN98068A1 (fr) 1997-05-28 1998-05-21 Composition pharmaceutique d'omeprazole
EG56898A EG24044A (en) 1997-05-28 1998-05-25 pharmaceutical formulation of omeprazole
MYPI98002355A MY122298A (en) 1997-05-28 1998-05-27 Pharmaceutical formulation of omeprazole
SA98190304A SA98190304B1 (ar) 1997-05-28 1998-07-19 صيغة صيدلانية من الأوميبرازول omeprazole
IS5245A IS2856B (is) 1997-05-28 1999-11-11 Lyfjablanda úr ómeprasól
NO19995809A NO328100B1 (no) 1997-05-28 1999-11-26 Farmasoytisk formulering av omeprazol
HK00105002A HK1025744A1 (en) 1997-05-28 2000-08-10 Pharmaceutical formulation of omeprazole

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702000A SE9702000D0 (sv) 1997-05-28 1997-05-28 New pharmaceutical formulation

Publications (1)

Publication Number Publication Date
SE9702000D0 true SE9702000D0 (sv) 1997-05-28

Family

ID=20407122

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9702000A SE9702000D0 (sv) 1997-05-28 1997-05-28 New pharmaceutical formulation

Country Status (41)

Country Link
US (1) US6090827A (is)
EP (1) EP0984773B1 (is)
JP (1) JP4649001B2 (is)
KR (1) KR100540721B1 (is)
CN (1) CN1123338C (is)
AR (1) AR012698A1 (is)
AT (1) ATE234078T1 (is)
AU (1) AU722879B2 (is)
BR (1) BR9809484A (is)
CA (1) CA2290531C (is)
CZ (1) CZ298972B6 (is)
DE (1) DE69812089T2 (is)
DK (1) DK0984773T3 (is)
DZ (1) DZ2494A1 (is)
EE (1) EE03903B1 (is)
EG (1) EG24044A (is)
ES (1) ES2195342T3 (is)
HK (1) HK1025744A1 (is)
HR (1) HRP980260B1 (is)
HU (1) HU229154B1 (is)
ID (1) ID24654A (is)
IL (1) IL132895A0 (is)
IS (1) IS2856B (is)
MA (1) MA26497A1 (is)
MY (1) MY122298A (is)
NO (1) NO328100B1 (is)
NZ (1) NZ500886A (is)
PL (1) PL194634B1 (is)
PT (1) PT984773E (is)
RS (1) RS49629B (is)
RU (1) RU2207121C2 (is)
SA (1) SA98190304B1 (is)
SE (1) SE9702000D0 (is)
SI (1) SI0984773T1 (is)
SK (1) SK286625B6 (is)
TN (1) TNSN98068A1 (is)
TR (1) TR199902890T2 (is)
TW (1) TW575435B (is)
UA (1) UA71541C2 (is)
WO (1) WO1998053803A1 (is)
ZA (1) ZA984178B (is)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
WO1999053918A1 (fr) * 1998-04-20 1999-10-28 Eisai Co., Ltd. Compositions stabilisees contenant des composes du type benzimidazole
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
WO2001028559A1 (fr) 1999-10-20 2001-04-26 Eisai Co., Ltd. Procede de stabilisation de composes benzimidazoles
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
JP2002234842A (ja) * 2001-02-09 2002-08-23 Kyowa Yakuhin Kogyo Kk 内服腸溶性製剤
MXPA04007169A (es) * 2002-01-25 2004-10-29 Santarus Inc Suministro transmucosal de inhibidores de bomba de protones.
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
FR2843121B3 (fr) 2002-08-02 2004-09-10 Rhodia Chimie Sa Agent ignifugeant, procede de preparation et l'utilisation de cet agent
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20040146558A1 (en) * 2003-01-28 2004-07-29 Kyowa Pharmaceutical Co., Ltd. Oral enteric-coated preparation
BRPI0407074A (pt) * 2003-01-29 2006-01-24 Takeda Pharmaceutical Método para produção de uma preparação revestida, preparação revestida, e, método para melhorar a dissolução do cloridreto de pioglitazona de uma preparação revestida com cloridreto de pioglitazona
JP4567340B2 (ja) * 2003-01-29 2010-10-20 武田薬品工業株式会社 被覆製剤の製造方法
ZA200506397B (en) * 2003-01-29 2006-11-29 Takeda Pharmaceutical Process for producing coated preparation
CA2517005A1 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
CN1311824C (zh) * 2004-04-21 2007-04-25 常州市第四制药厂有限公司 奥美拉唑肠溶微粒制剂及制备方法
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2324354T3 (es) * 2005-07-29 2009-08-05 Rottapharm S.P.A. Combinacion terapeutica de itriglumida e inhibidores de la bomba de protones en el tratamiento de trastornos gastrointestinales y relacionados.
AU2007266574A1 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
KR101436516B1 (ko) * 2007-07-23 2014-09-02 주식회사태평양제약 코팅된 펠렛을 함유하는 현탁정 및 이의 제조방법
EP2205218A4 (en) * 2007-09-28 2010-11-17 Ctc Bio Inc ESOMEPRAZOLE-CONTAINING PHARMACEUTICAL COMPOSITION
DK2273985T3 (en) * 2008-03-28 2016-04-25 Ferrer Int Capsule for the prevention of cardiovascular diseases
PL2334378T3 (pl) 2008-08-19 2014-09-30 Xenoport Inc Proleki wodorofumaranu metylu, ich kompozycje farmaceutyczne i sposoby zastosowania
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
JP2015526477A (ja) 2012-08-22 2015-09-10 ゼノポート，インコーポレイティド メチル水素フマレートの経口剤形およびそのプロドラッグ
CN102961356A (zh) * 2012-12-11 2013-03-13 山西云鹏制药有限公司 一种含奥美拉唑的蓝色肠溶片剂的制备方法
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
US9416096B2 (en) 2013-09-06 2016-08-16 Xenoport, Inc. Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
WO2015042294A1 (en) * 2013-09-18 2015-03-26 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2021153525A1 (ja) 2020-01-27 2021-08-05 東和薬品株式会社 エソメプラゾール経口製剤およびその製造方法
KR102432084B1 (ko) 2021-11-16 2022-08-12 알리코제약(주) S-오메프라졸을 함유하는 안정성이 개선되고 소형화된 정제
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH05255088A (ja) * 1991-11-05 1993-10-05 Yoshitomi Pharmaceut Ind Ltd 抗潰瘍剤含有製剤
JP2669446B2 (ja) * 1992-03-23 1997-10-27 信越化学工業株式会社 医薬品コーティング液用原料粉粒体
JPH0733659A (ja) * 1992-07-17 1995-02-03 Yoshitomi Pharmaceut Ind Ltd 抗潰瘍剤含有製剤
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
EP0723436B1 (en) * 1994-07-08 2001-09-26 AstraZeneca AB Multiple unit tableted dosage form i
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms

Also Published As

Publication number Publication date
UA71541C2 (uk) 2004-12-15
ATE234078T1 (de) 2003-03-15
JP4649001B2 (ja) 2011-03-09
DZ2494A1 (fr) 2003-01-25
ZA984178B (en) 1998-11-30
ID24654A (id) 2000-07-27
HRP980260B1 (en) 2003-10-31
IL132895A0 (en) 2001-03-19
RU2207121C2 (ru) 2003-06-27
DE69812089T2 (de) 2004-03-04
US6090827A (en) 2000-07-18
JP2002500665A (ja) 2002-01-08
SK159099A3 (en) 2000-06-12
YU60899A (sh) 2002-06-19
ES2195342T3 (es) 2003-12-01
WO1998053803A1 (en) 1998-12-03
NO328100B1 (no) 2009-12-07
EP0984773A1 (en) 2000-03-15
MA26497A1 (fr) 2004-12-20
SA98190304B1 (ar) 2006-10-11
TNSN98068A1 (fr) 2005-03-15
PL337237A1 (en) 2000-08-14
HU229154B1 (en) 2013-09-30
RS49629B (sr) 2007-08-03
AU722879B2 (en) 2000-08-10
CA2290531A1 (en) 1998-12-03
DK0984773T3 (da) 2003-07-07
SI0984773T1 (en) 2003-10-31
BR9809484A (pt) 2000-06-20
PL194634B1 (pl) 2007-06-29
AU7680398A (en) 1998-12-30
NZ500886A (en) 2001-11-30
HUP0002182A3 (en) 2003-02-28
KR20010013104A (ko) 2001-02-26
EP0984773B1 (en) 2003-03-12
HUP0002182A2 (hu) 2002-05-29
AR012698A1 (es) 2000-11-08
HRP980260A2 (en) 1999-02-28
MY122298A (en) 2006-04-29
CZ420299A3 (cs) 2000-05-17
NO995809L (no) 2000-01-28
TR199902890T2 (xx) 2000-02-21
CN1123338C (zh) 2003-10-08
EG24044A (en) 2008-04-13
HK1025744A1 (en) 2000-11-24
DE69812089D1 (de) 2003-04-17
EE9900540A (et) 2000-06-15
IS5245A (is) 1999-11-11
CZ298972B6 (cs) 2008-03-26
CA2290531C (en) 2006-12-12
CN1258217A (zh) 2000-06-28
EE03903B1 (et) 2002-12-16
PT984773E (pt) 2003-07-31
TW575435B (en) 2004-02-11
NO995809D0 (no) 1999-11-26
KR100540721B1 (ko) 2006-01-10
SK286625B6 (sk) 2009-02-05
IS2856B (is) 2013-11-15

Similar Documents

Publication Publication Date Title
SE9702000D0 (sv) New pharmaceutical formulation
DK1124539T3 (da) Farmaceutisk formulering der omfatter omeprazol
DK1191926T3 (da) Ny omeprazol- og (S)-omeprazolformulering
ME00318B (me) Nova kompozicija i njena upotreba
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
SE0100200D0 (sv) New film coating
ES2185452A1 (es) Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.
ATE110379T1 (de) Therapeutisch aktive substituierte benzimidazole und verfahren zu ihrer herstellung.
YU242789A (en) New compound, 4-fluoro-2-//(4-metoxy-2-pyridin-yl)methylsulphinyl/-1h-benzimidazole and process for obtaining
HUP0203310A2 (hu) Benzimidazolszármazékot tartalmazó stabil gyógyszerkészítmények és eljárás ezek előállítására
JO1653B1 (en) The current benzimidazole is a therapeutically active method for preparing it